Genomic Health, Inc. (GHDX) Stock: Here’s What’s Happening

0

Genomic Health, Inc. (GHDX) is headed up in the market in today’s trading session. The company, one that is focused in the biotech industry, is presently trading at $62.26 after a move up of 9.68% so far in today’s session. As it relates to biotech companies, there are a number of aspects that have the ability to lead to movement in the market. News is one of the most common reasons for movement. Here are the recent stories associated with GHDX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-24-19 07:08AM The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index
Jul-23-19 06:17PM Genomic Health Set to Join S&P SmallCap 600
Jun-24-19 02:46PM What You Must Know About Genomic Health, Inc.’s (NASDAQ:GHDX) Financial Health
02:43PM Genomic Health, Inc. (NASDAQ:GHDX): Will The Growth Last?
Jun-20-19 01:00PM German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test

Nonetheless, when making a decision with regard to investing, prospective investors should look into much more than news, especially in the speculative biotechnology industry. Here’s what’s happening with Genomic Health, Inc..

Recent Trends From GHDX

While a move up on a single session, like what we’re seeing from Genomic Health, Inc. may make some investors happy, a single session move alone should not be the basis of a decision to, or not to, invest in a company. It’s always important to look at trends experienced by the stock further out than a single trading day. In the case of GHDX, here are the returns on investment that we’ve seen:

  • Weekly – Throughout the last five trading sessions, GHDX has produced a price change amounting to 1.28%.
  • Past 30 Days – The monthly performance from Genomic Health, Inc. has been 3.52%.
  • Past Quarter – In the past three months, the stock has produced a return on investment that comes to -13.89%
  • Past 6 Months – In the previous 6 months, we have seen a performance that amounts to -20.04% from the company.
  • Year To Date – Since the close of last year GHDX has generated a return of -11.86%.
  • Annually – Lastly, throughout the past full year, we’ve seen movement of -0.99% from GHDX. Over this period of time, the stock has sold at a high price of -32.45% and a low of 22.64%.

Crucial Ratios

Digging into a few ratios having to do with a company can give prospective investors a view of how risky and/or potentially profitable a an investment option might be. Here are some of the key ratios to consider when looking at GHDX.

Short Ratio – The short ratio is a tool that’s used to measure the amount of short interest. As the short ratio goes higher, it shows that more investors have a belief that the stock is headed for declines. Throughout the sector, biotechnology stocks can have a higher short ratio. However, we also see quite a few short squeezes in the industry. Nonetheless, as it relates to Genomic Health, Inc., the stock’s short ratio clocks in at 3.30.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure the company’s abilities to pay for its debts as they mature based on current assets or quick assets. In the biotech sector, many companies are heavily reliant on continued support from investors, these ratios can look upsetting. However, quite a few good picks in the biotechnology sector do have positive current and quick ratios. When it comes to GHDX, the quick and current ratios add up to 5.70 and 5.70 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets owned by the company. as it relates to Genomic Health, Inc., the book to share value ratio works out to 7.84.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is a very important ratio to look into. When it comes to GHDX, the cash to share value ratio works out to 5.53.

How Analysts Feel About Genomic Health, Inc.

While it’s not a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their thoughts when validating your own opinions before making investment decisions in the biotech sector. Here are the recent moves that we’ve seen from analysts as it relates to GHDX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-20-19 Upgrade Piper Jaffray Neutral → Overweight $72
May-09-19 Reiterated Needham Strong Buy $97 → $69
Feb-21-19 Reiterated Needham Strong Buy $86 → $97
Jan-03-19 Initiated Needham Strong Buy $86
Dec-19-18 Initiated Oppenheimer Perform

Is Big Money Interested In Genomic Health, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in GHDX, here’s what we’re seeing:

  • Institutional Investors – Currently, institutional investors own 94.50% of GHDX. On the other hand, it’s worth considering that institutional ownership has seen a move of -2.51% over the last quarter.
  • Investors On The Inside – with regard to insiders, members of the management team and others close to GHDX currently hold 0.70% of Genomic Health, Inc.. Insider ownership of the company has seen a move of -91.36% in the last 3 months.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 37.22M shares of Genomic Health, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, GHDX has a float of 36.16M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to GHDX, the short percent of the float is 4.46%.

What We’ve Seen In earnings results

What have ween seen from GHDX in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts expect that GHDX will come up with earnings per diluted share that comes to 1.63, with 0.35 being reported in the earnings report for the current quarter. Although this isn’t associated with earnings, since we are talking on the topic of analysts, Genomic Health, Inc. is presently rated a 2.70 considering a scale that ranges from 1 to 5 where 1 is the poorest analyst grade and 5 is the best.
  • 5-Year Sales – Over the last 5 years, Genomic Health, Inc. has created a change in sales volume that works out to be 8.50%. Earnings through the period have experienced movement in the amount of 29.70%.
  • Q/Q – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally represented in the human world, Genomic Health, Inc. has seen a earnings change by 412.70%. Genomic Health, Inc. has also seen a change when it comes to sales volume that amounts to 17.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an AI. So, by my very nature, I have the ability to learn by myself. However, I was made by a human and human beings play a crucial part in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you would to help me learn something, I would love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here